• Publications
  • Influence
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
The American Society for Apheresis (ASFA) JCA Special Issue Writing Committee is charged with reviewing, updating and categorizating indications for therapeutic apheresis. Beginning with the 2007Expand
  • 514
  • 57
  • PDF
Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis
The American Society for Apheresis (ASFA) Apheresis Applications Committee is charged with a review and categorization of indications for therapeutic apheresis. Beginning with the 2007 ASFA SpecialExpand
  • 527
  • 47
Transfusion-related acute lung injury: incidence and risk factors.
Transfusion-related acute lung injury (TRALI) is the leading cause of transfusion-related mortality. To determine TRALI incidence by prospective, active surveillance and to identify risk factors by aExpand
  • 422
  • 29
  • PDF
Transfusion-related acute lung injury in the critically ill: prospective nested case-control study.
RATIONALE Acute lung injury (ALI) that develops 6 hours after transfusion (TRALI) is the leading cause of transfusion-related mortality. Several transfusion characteristics have been postulated asExpand
  • 401
  • 27
  • PDF
Deployment of convalescent plasma for the prevention and treatment of COVID-19.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease (COVID-19), has spurred a global health crisis. To date, there are no proven options for prophylaxis forExpand
  • 412
  • 23
  • PDF
Fresh-frozen plasma and platelet transfusions are associated with development of acute lung injury in critically ill medical patients.
BACKGROUND Transfusion has long been identified as a risk factor for acute lung injury (ALI)/ARDS. No study has formally evaluated the transfusion of specific blood products as a risk factor forExpand
  • 354
  • 15
Early safety indicators of COVID-19 convalescent plasma in 5,000 patients.
BACKGROUND Convalescent plasma is the only antibody based therapy currently available for COVID 19 patients. It has robust historical precedence and sound biological plausibility. Although promising,Expand
  • 234
  • 14
  • PDF
A Comparison of Plasmapheresis Versus High‐Dose IVIG Desensitization in Renal Allograft Recipients with High Levels of Donor Specific Alloantibody
Several protocols allow for the successful transplantation of sensitized renal allograft recipients, yet no one best method has emerged. The aim of the current study was to compare the efficacy ofExpand
  • 366
  • 12
Transfusion‐related acute lung injury and pulmonary edema in critically ill patients: a retrospective study
BACKGROUND: Using the recent Consensus Panel recommendations, we sought to describe the incidence of transfusion‐related acute lung injury (TRALI) and transfusion‐associated circulatory overloadExpand
  • 260
  • 12
Histologic Findings One Year After Positive Crossmatch or ABO Blood Group Incompatible Living Donor Kidney Transplantation
Recent protocols have allowed successful positive crossmatch (+XM) and ABO incompatible (ABOI) kidney transplantation, although their long‐term outcome is not clear. To begin to assess this issue weExpand
  • 182
  • 11
...
1
2
3
4
5
...